JPMorgan on PTC Therapeutics (PTCT): 'Despite Notable Unknowns for Clinical & Regulatory Outlook, 12-mo PIVOT-HD Update Solidly Encouraging on All Fronts'
Tweet Send to a Friend
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $53.00 price target on PTC Therapeutics (NASDAQ: PTCT).The analyst comments "With ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
